Price T Rowe Associates Inc Blueprint Medicines Corp Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,387,267 shares of BPMC stock, worth $606 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
5,387,267
Previous 5,873,392
8.28%
Holding current value
$606 Million
Previous $633 Million
21.28%
% of portfolio
0.06%
Previous 0.08%
Shares
16 transactions
Others Institutions Holding BPMC
# of Institutions
355Shares Held
60.7MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$752 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$748 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$446 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$311 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.67MShares$188 Million0.4% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $6.72B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...